GlobeNewswire

Karolinska Development's portfolio company Forendo Pharma commences Phase 1b study of its drug candidate FOR-6219

Dela

STOCKHOLM – August 20, 2019. Karolinska Development (Nasdaq Stockholm: KDEV) announces today that its portfolio company Forendo Pharma has initiated dosing in a Phase 1b clinical study with the aim to demonstrate Proof of Mechanism for FOR-6219 – a drug candidate intended for the treatment of endometriosis.  

Endometriosis is a chronic condition that affects up to 10 per cent of women in reproductive age and causes repeated pain symptoms, infertility and impaired quality of life. Currently available treatments have limitations in efficacy or cause harmful side effects due to estrogen depletion. FOR-6219 is a HSD17B1 inhibitor aiming to reduce estrogen production locally in the endometriosis lesions.

In the Phase 1b study, FOR-6219 will be administered to healthy premenopausal women to explore its effect on the endometrium by measuring changes in endometrial thickness and endometrial estrogen levels. In addition to these local effects, systemic hormone levels will be measured. The study will also provide further safety and tolerability data.

“A positive outcome of this important Phase 1b study would further strengthen the hypothesis that Forendo Pharma’s lead drug candidate has potential to transform the treatment of endometriosis, based on its unique ability to selectively inhibit local estrogen production”, said Viktor Drvota, CEO of Karolinska Development.  


For further information, please contact :

Viktor Drvota, CEO, Karolinska Development AB
Phone: +46 73 982 52 02, e-mail: viktor.drvota@karolinskadevelopment.com

TO THE EDITORS

About Karolinska Development AB
Karolinska Development AB (Nasdaq Stockholm: KDEV) is a Nordic life sciences investment company. The company focuses on identifying breakthrough medical innovations in the Nordic region that are developed by entrepreneurs and leadership teams. The Company invests in the creation and growth of companies that advance these assets into commercial products that are designed to make a difference to patients' lives while providing an attractive return on investment to shareholders.

Karolinska Development has access to world-class medical innovations at the Karolinska Institutet and other leading universities and research institutes in the Nordic region. The Company aims to build companies around scientists who are leaders in their fields, supported by experienced management teams and advisers, and co-funded by specialist international investors, to provide the greatest chance of success.

Karolinska Development has established a portfolio of ten companies targeting opportunities in innovative treatment for life-threatening or serious debilitating diseases.

The Company is led by an entrepreneurial team of investment professionals with a proven track record as company builders and with access to a strong global network.

For more information, please visit www.karolinskadevelopment.com


Bilaga

Om

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Följ GlobeNewswire

Abonnera på våra pressmeddelanden. Endast mejladress behövs och den används bara här. Du kan avanmäla dig när som helst.

Senaste pressmeddelandena från GlobeNewswire

CONDITIONS FOR RIKSBANK BID PROCEDURE KOMMUNINVEST BONDS14.8.2020 16:20:00 CESTPress release

Sveriges Riksbank Bid procedure details Kommuninvest Bonds, 2020-08-18 Maturity dateLoanISIN codeCouponVolume, SEK million2022-06-012206SE00092694180.25 %500 +/- 2502023-11-132311SE00109482401.00 %500+/- 2502025-05-12 2505 SE0011414010 1.00 % 500+/- 250 2026-11-12 2611 SE0012569572 1.00 % 500+/- 250 Maximum volume 2 000 million in total Settlement date 2020-08-20 Bids have to be entered by 11.00 on AUG 18, 2020 Highest permitted bid volume: 500 SEK million in issue 2206, 2311, 2505, and 2611. Lowest permitted bid volume: 50 SEK million Bids only through counterparties approved by the Riksbank RESULT OF AUCTION WILL BE PUBLISHED NO LATER THAN 11.15 (CEST) ON AUG 18, 2020 For more information, please contact: Trading desk at the Riksbank + 46 8 696 6970 General and special terms and conditions can be retrieved at http://www.riksbank.se

CONDITIONS FOR RIKSBANK BID PROCEDURES SEK GOVERNMENT BONDS14.8.2020 16:20:00 CESTPress release

Sveriges Riksbank Bid procedure details Government Bonds, 2020-08-21 Maturity dateLoanISIN codeCouponVolume, SEK million2028-05-121060SE00094963670.75 %1000 +/- 2502031-05-121062 SE00139353190.125 1000 +/- 250 Settlement date 2020-08-25 Bids have to be entered by 10.00 on AUG 21, 2020 Highest permitted bid volume: 1000 SEK million in issue SGB 1060 and 1000 SEK million in issue SGB 1062 Lowest permitted bid volume: 50 SEK million Bids only through counterparties approved by the Riksbank RESULT OF AUCTION WILL BE PUBLISHED NO LATER THAN 10.10 (CEST)ON AUG 21, 2020. For more information, please contact: Trading desk at the Riksbank + 46 8 696 6970 General and special terms and conditions can be retrieved at http://www.riksbank.se

SEK CREDIT OPERATION ANNOUNCEMENT14.8.2020 16:20:00 CESTPress release

SEK CREDIT OPERATION ANNOUNCEMENT 2020-08-18 Transaction type:SEK CreditTender date:2020-08-18Time for submission of bids:11.00-11.30 (CEST)Payment date:2020-08-18 (at 3 pm)Maturity date:2020-11-16Duration:13 weeks. For credit in consequence of the auction on 18 August 2020, the maturity is however 12 weeks and 6 daysOffered volume:UnlimitedLowest accepted bid volumeSEK 50 millionMaximum number of bids from each participant: 1RateRepo rate Transaction type:SEK CreditTender date:2020-08-18Time for submission of bids:11.00-11.30 (CEST)Payment date:2020-08-18 (at 3 pm)Maturity date:2021-02-15Duration:26 weeks. For credit in consequence of the auction on 18 August 2020, the maturity is however 25 weeks and 6 days. Offered volume:UnlimitedLowest accepted bid volumeSEK 50 millionMaximum number of bids from each participant: 1RateRepo rate All monetary counterparties are invited to submit volume bids to the Riksbank, tel + 46 8 6966970 by 11.30 am on August 18, 2020. Confirmation of bids to e

CONDITIONS FOR RIKSBANK BID PROCEDURES SEK COVERED BONDS14.8.2020 16:20:00 CESTPress release

Sveriges Riksbank Bid procedure details Covered Bonds, 2020-08-20 Maturity dateLoanISIN codeCouponVolume, SEK million2025-09-175535 SE00133584131.00 %1,000 +/- 5002024-12-18579 SE00121936211.00 %1,000 +/- 500 2024-12-031589SE00116433861.50 %1,000 +/- 5002025-06-18195SE00135460661.00 %1,000 +/- 5002024-12-182412SE00126218521.00 %400 +/- 2502025-09-17518SE00113092441.25 %400 +/- 2502025-06-11146SE00133815711.00 %400 +/- 250 Settlement date 2020-08-24 Bids have to be entered by 10.00 on AUG 20 2020 Highest permitted bid volume: 1,000 SEK million in issue 5535 1,000 SEK million in issue 579 1,000 SEK million in issue 1589 1,000 SEK million in issue 195 400 SEK million in issue 2412 400 SEK million in issue 518 400 SEK million in issue 146 Maximum volume 5 billion SEK in total Lowest permitted bid volume: 50 SEK million Bids only through counterparties approved by the Riksbank RESULT OF AUCTION WILL BE PUBLISHED NO LATER THAN 10.15 (CEST) ON AUG 20, 2020. For more information, please conta

NEXSTIM ABP:S HALVÅRSRAPPORT 1/1–30/6 2020 (OREVIDERAD)14.8.2020 14:00:00 CESTPressemelding

Företagsmeddelande, Insiderinformation, Helsingfors 14 augusti 2020 kl. 15.00 (EEST) NEXSTIM ABP:S HALVÅRSRAPPORT 1/1–30/6 2020 (OREVIDERAD) Viktiga händelser januari–juni 2020 Vi fokuserade på att minimera effekterna av covid-19-pandemin och utforma en ny strategi. Med tanke på den svåra affärsmiljön gjorde vi goda framsteg genom att sälja fyra nya NBS-system, tre i USA och ett i EU och installera fem nya NBT®-system på kliniker i USA och Europa för behandling av egentlig depression. Halvåret 1/1–30/6 2020 var det bästa någonsin för bolaget, med avseende på omsättningen, rörelseresultatet och räkenskapsperiodens resultat. Bolagets totala omsättning under första halvåret var 1,6 miljoner euro (H1 2019: 1,2 mn euro), rörelseresultatet var -1,8 miljoner euro (H1 2019: -3,4 mn euro) och räkenskapsperiodens resultat var -1,2 miljoner euro (H1 2019: -3,7 mn euro). Under första halvåret ökade omsättningen för NBS (med 47 %) till 0,9 miljoner euro (H1 2019: 0,2 mn euro) och för NBT (med 18 %)

NEXSTIM PLC HALF-YEARLY REPORT 1 JANUARY – 30 JUNE 2020 (UNAUDITED)14.8.2020 14:00:00 CESTPress release

Company announcement, Inside Information, Helsinki, 14 August 2020 at 15:00 (EEST) NEXSTIM PLC HALF-YEARLY REPORT 1 JANUARY – 30 JUNE 2020 (UNAUDITED Highlights, January – June 2020 Focused on minimizing the effect of COVID-19 pandemic as well as updating company strategy. Considering the difficult business environment, good progress with four new NBS systems sold, three in the US one in the EU and a total of five new NBT® systems installed to clinics in the US and Europe, across multiple sites, for the treatment of Major Depressive Disorder (MDD) January 1 – June 30, 2020 was historically the Company’s best first half to date when measured by net sales, operating result and result for the period. The total net sales in the first half was EUR 1.6 million (2019 H1: EUR 1.2 million), operating result EUR -1.8 million (2019 H1: -3.4 million) and result for the period EUR -1.2 million (2019 H1: EUR -3.7 million) NBS net sales grew by 47% in H1 to EUR 0.9 million (2019 H1: EUR 0.6 million)